Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05558982 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Study acronym: EXPEL PANC
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completion moved earlier from Nov 2027 to Sep 2027 Study sites: 3 to 1v12 Show 1 more changeShow less
    • Study sites: 3 to 1
  2. Primary completion date changed from estimate of Jan 1, 2026 to Dec 31, 2025v11
  3. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 43 to confirmed 22 · Primary completion date: Nov 2026 to Jan 1, 2026 · Site details revised at 3 of 3 sitesv10 Show 3 more changesShow less
    • Enrollment target: estimated 43 to confirmed 22
    • Primary completion date: Nov 2026 to Jan 1, 2026
    • Site details revised at 3 of 3 sites
  4. Site contacts updated at 1 of 3 sitesv9
  5. Site contacts updated at 1 of 3 sitesv8
Show 6 earlier versionsHide 6 earlier versions
  1. Study sites: 1 to 3v7
  2. Start date changed from estimate of Jul 2023 to Aug 16, 2023v6
  3. Trial status: Not Yet Recruiting to Recruiting Site details revisedv5 Show 1 more changeShow less
    • Site details revised
  4. Start date: Mar 2023 to Jul 2023v4
  5. Site contact updated Collaborators: 1 to 2v3 Show 1 more changeShow less
    • Collaborators: 1 to 2

    See this version in full on ClinicalTrials.gov ↗

  6. Start date: Dec 2022 to Mar 2023v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Single-arm, open label study to determine the 18 week progression-free survival rate of the combination of BXCL701 and pembrolizumab in patients with pancreatic ductal adenocarcinoma in the second-line metastatic setting.
Trial Details
NCT Number NCT05558982
Lead Sponsor Georgetown University
Collaborators: BioXcel Therapeutics Inc, Merck Sharp & Dohme LLC
Conditions Metastatic Pancreatic Ductal Adenocarcinoma
Enrollment 22 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov